01:31 AM EDT, 09/24/2026 (MT Newswires) -- Fitch Ratings on Wednesday affirmed its long-term issuer default rating on Roche (RO.SW) at AA, with a stable outlook. The affirmation is backed by the Swiss drugmaker's strong footprint across multiple therapeutic areas and its "attractive" growth pipeline. Fitch expects Roche's pharma division to maintain mid-single-digit growth annually, with the group expected to deliver mid-single-digit organic growth from 2026 through 2029. The rating agency also expects Roche to continue investing in manufacturing capacity to support future treatment launches, along with laboratories and site infrastructure over the medium term.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.